Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Bisantrene's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Bisantrene. Showing past 6 months and next 12 months · 6 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Bisantrene | Racura Oncology | Small Molecule Other | Phase 2 | 0 | ||||
| SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma | Sarcoma Alliance for Research through Collaboration | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | European Organisation for Research and Treatment of Cancer - EORTC | — | Phase 3 | — | — | — | — | — |
| A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | Rezolute | — | Phase 3 | — | — | — | — | — |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | National Cancer Institute (NCI) | — | Phase 3 | — | — | — | — | — |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | National Cancer Institute (NCI) | — | PHASE2/PHASE3 | — | — | — | — | — |
| Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | Fox Chase Cancer Center | — | Phase 2 | — | — | — | — | — |
| Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | USWM CT, LLC | — | Phase 2 | — | — | — | — | — |
| Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma | USWM, LLC (dba US WorldMeds) | — | Phase 2 | — | — | — | — | — |
| Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | USWM CT, LLC | — | Phase 2 | — | — | — | — | — |
| Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | USWM CT, LLC | — | Phase 2 | — | — | — | — | — |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | HRYZ Biotech Co. | — | Phase 2 | — | — | — | — | — |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | National Cancer Institute LAO | — | Phase 2 | — | — | — | — | — |
| First-line Treatment of Advanced/unresectable DDLPS | Fudan University | — | Phase 2 | — | — | — | — | — |
| Palbociclib and INCMGA00012 in People With Advanced Liposarcoma | Memorial Sloan Kettering Cancer Center | — | Phase 2 | — | — | — | — | — |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma | M.D. Anderson Cancer Center | — | Phase 2 | — | — | — | — | — |
| Study of Abemaciclib in Dedifferentiated Liposarcoma | Memorial Sloan Kettering Cancer Center | — | Phase 2 | — | — | — | — | — |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | Pfizer | — | Phase 2 | — | — | — | — | — |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| APX005M and Doxorubicin in Advanced Sarcoma | Alexander Z. Wei, MD | — | Phase 2 | — | — | — | — | — |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | Memorial Sloan Kettering Cancer Center | — | Phase 2 | — | — | — | — | — |
| Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma | Alliance for Clinical Trials in Oncology | — | Phase 2 | — | — | — | — | — |
| Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery | M.D. Anderson Cancer Center | — | Phase 2 | — | — | — | — | — |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) | Fudan University | — | Phase 2 | — | — | — | — | — |
| A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) | Lund University Hospital | — | Phase 2 | — | — | — | — | — |
| A Study of Pembrolizumab in People With Ultra-Rare Sarcomas | Memorial Sloan Kettering Cancer Center | — | Phase 2 | — | — | — | — | — |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma | Oslo University Hospital | — | Phase 2 | — | — | — | — | — |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. | Oslo University Hospital | — | Phase 2 | — | — | — | — | — |
| BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors | Sotio Biotech Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors | Lamassu Bio Inc | — | PHASE1/PHASE2 | — | — | — | — | — |
| APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | Ascentage Pharma Group Inc. | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | Shanghai Pharmaceuticals Holding Co., Ltd | — | PHASE1/PHASE2 | — | — | — | — | — |
| Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | National Cancer Institute (NCI) | — | PHASE1/PHASE2 | — | — | — | — | — |
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | STORM Therapeutics LTD | — | PHASE1/PHASE2 | — | — | — | — | — |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | Grupo Espanol de Investigacion en Sarcomas | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma | Memorial Sloan Kettering Cancer Center | — | PHASE1/PHASE2 | — | — | — | — | — |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Milton S. Hershey Medical Center | — | PHASE1/PHASE2 | — | — | — | — | — |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | St. Jude Children's Research Hospital | — | PHASE1/PHASE2 | — | — | — | — | — |